BRAINSTORM CELL THERAPEUTICS INC.
Close on Oct 19, 2026
- Market cap
- $8.50M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | During market hours | – | $-0.19 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | During market hours | – | $-0.19 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.34 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | During market hours | – | $-0.45 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | – | – |
Press releases
Announcements Brainstorm Cell Therapeutics filed with the SEC
BrainStorm Cell Therapeutics Announces Second
Results of operations · EX-99.1 to Form 8-K
Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces First
Results of operations · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Full
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
BrainStorm Announces New Survival Data from
Other events · EX-99.1 to Form 8-K
BrainStorm Receives FDA Clearance to Initiate
Other events · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces First
Results of operations · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
involve risks and uncertainties that could cause Brainstorm Cell Therapeutics Inc.'s actual results to differ materially from
Regulation FD disclosure · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Second
Results of operations · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Pricing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn ® Clinical Trial
Other events · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Management Changes as Company
Executive or director change · Other events · EX-99.1 to Form 8-K
Regains Compliance with NASDAQ Minimum Market Value Rule
Other events · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Agreement with FDA on a
Other events · EX-99.1 to Form 8-K
Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
BrainStorm Issues 2023 Letter to
Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces In-Person
Other events · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Third
Results of operations · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Strategic
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Second
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces FDA Advisory
Regulation FD disclosure · EX-99.1 to Form 8-K
Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces FDA Advisory Committee
Regulation FD disclosure · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Third
Results of operations · EX-99.1 to Form 8-K
BrainStorm Presents New Biomarker Analyses
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
The Relationship between CSF Biomarkers and Efficacy of Treatment with NurOwn (MSC - NTF cells) ALS ONE, Industry Presentations Stacy R. Lindborg, Ph.D. Chief Development Officer, Brainstorm Cell Therapeutics October 7, 2022
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces First
Results of operations · EX-99.1 to Form 8-K
Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial
Results of operations · EX-99.1 to Form 8-K
Third Quarter 2021 Earnings Call
Results of operations · EX-99.2 to Form 8-K